On Tuesday, Shares of Omeros Corporation (NASDAQ:OMER), skyrocketed 72.03% to $25.03, hitting its highest level.
Omeros Corporation declared additional positive data in the company’s Phase 2 clinical trial of OMS721 for the treatment of thrombotic microangiopathies (TMAs). TMAs are a family of rare, debilitating and life-threatening disorders characterized by excessive thrombi (clots) – aggregations of platelets – in the microcirculation of the body’s organs, most commonly the kidney and brain. OMS721 is Omeros’ lead human monoclonal antibody in its mannan-binding lectin-associated serine protease-2 (MASP-2) program for the treatment of TMAs, counting atypical hemolytic uremic syndrome (aHUS).
The Phase 2 trial is designed to enroll primarily aHUS patients but can also enroll patients with thrombotic thrombocytopenic purpura (TTP) and hematopoietic stem cell transplant (HSCT)-related TMA. The trial has fully enrolled the first and second cohorts and is presently concluding the third and final planned cohort of its dose-ranging stage. In each three-patient cohort, OMS721 is dosed for four weeks. Data from the first (low-dose) cohort were released on February 19, 2015. Recently the company is releasing data from its second (mid-dose) cohort and data to date from its third (high-dose) cohort.
Three patients were treated in the second or mid-dose cohort, two of whom have aHUS and one with TTP. Both patients with aHUS were on renal dialysis preceding to and at the time of study enrollment. Based on the positive data from the mid-dose cohort, the high-dose cohort was initiated and an aHUS patient has already accomplished the study treatment period. No patient with HSCT-related TMA has yet accomplished dosing with OMS721. The data referenced for all patients comprise measures to one week following the last dose.
Omeros Corporation, a biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. It markets Omidria for use during cataract surgery or intraocular lens, or replacement surgery.
Shares of Xerox Corporation (NYSE:XRX), declined -0.44% to $11.32, during its last trading session.
Xerox Corporation was downgraded by analysts at Zacks from a hold rating to a sell rating. According to Zacks, “Xerox stated disappointing second-quarter 2015 results as earnings and revenues reduced year over year and adjusted earnings missed the Zacks Consensus Estimate by $0.01. The presence of a large number of substitutes and strong competition are likely to peg back its profitability to some extent. Fluctuations in foreign currency exchange rates affect the company’s net investment in foreign auxiliaries and may cause instability in cash flows. However, Xerox is intensely focused on improving its services margin and implementing restructuring actions and prioritizing investments to accelerate benefits in the future quarters. The company also remains committed to its strategy that is centered on portfolio administration, operational excellence, global growth and cost transformation. “
Xerox Corporation provides business process and document administration solutions worldwide. The company’s Services segment offers various business process outsourcing services, such as customer care, transaction processing, human resources, communication and marketing, and consulting and analytics services, in addition to finance, accounting, and procurement services.
Finally, BP p.l.c. (NYSE:BP), ended its last trade with -0.79% loss, and closed at $35.25.
BP PLC’s $18.7 billion settlement for its 2010 oil spill may not end lawsuits filed by two public university systems against the oil giant, a newspaper stated Sunday, according to AP.
Since many details are under wraps, it hasn’t been clear whether the settlement comprises the universities, but the attorney handling the university systems’ claims issued a statement last week saying he believes those claims remain open, The New Orleans Advocate stated. AP Reports
The Louisiana attorney general’s office did not respond to requests for comment. BP spokesman Geoff Morrell declined comment.
No public colleges or universities in Mississippi filed claims against BP, according to the Mississippi Attorney General’s Office. AP added.
The University of West Florida in Pensacola, which has nearly 12,000 students, settled its claims for nearly $178,000, spokeswoman Megan Gonzalez told AP.
BP p.l.c. operates as an integrated oil and gas company worldwide. It operates in three segments: Upstream, Downstream, and Rosneft. The Upstream segment engages in the oil and natural gas exploration, field development, and production; midstream transportation, and storage and processing; and marketing and trade of natural gas, counting liquefied natural gas (LNG), and power and natural gas liquids (NGL).
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
